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Abstract
Background: B-cell precursor acute lymphoblastic leukemia (B-ALL) is amongst the leading causes of childhood
cancer-related mortality. Its most common chromosomal aberration is the ETV6-RUNX1 fusion gene, with ~25 % of
ETV6-RUNX1 patients also carrying PAX5 alterations.
Methods: We have recreated this mutation background by inter-crossing Etv6-RUNX1 (Etv6RUNX1-SB) and Pax5+/− mice
and performed an in vivo analysis to find driver genes using Sleeping Beauty transposon-mediated mutagenesis and also
exome sequencing.
Results: Combination of Etv6-RUNX1 and Pax5+/− alleles generated a transplantable B220 + CD19+ B-ALL with a
significant disease incidence. RNA-seq analysis showed a gene expression pattern consistent with arrest at the pre-B
stage. Analysis of the transposon common insertion sites identified genes involved in B-cell development (Zfp423) and
the JAK/STAT signaling pathway (Jak1, Stat5 and Il2rb), while exome sequencing revealed somatic hotspot mutations in
Jak1 and Jak3 at residues analogous to those mutated in human leukemias, and also mutation of Trp53.
Conclusions: Powerful synergies exists in our model suggesting STAT pathway activation and mutation of Trp53 are
potent drivers of B-ALL in the context of Etv6-RUNX1;Pax5+/−.
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Background
B-cell precursor acute lymphoblastic leukemia (B-ALL)
is the most common childhood tumor [1]. The most
common chromosomal rearrangement in B-ALL is the
t(12;21)(p13;q22) translocation generating the ETV6-
RUNX1 fusion gene [2]. This fusion is necessary but insuf-
ficient for the development of B-ALL, as monozygotic
twin studies, and the detection of the ETV6-RUNX1 fu-
sion in fetal blood spots from patients who do not go on
to develop B-ALL have shown [3, 4].
PAX5, a guardian of B-cell identity and function, is som-
atically mutated in ~40 % of cases of childhood B-ALL [5].
Moreover, the most common recurrent focal deletion region
in ETV6-RUNX1+ tumors involves PAX5 (9p13.2; 25 %)
and these deletions are thought to be early events in
leukemogenesis [6]. Previously, we generated a knock-in
mouse model of ETV6-RUNX1 ALL, in which expression
of the fusion gene is driven from the endogenous Etv6
promoter, and is linked to expression of the Sleeping
Beauty (SB) transposase allowing the identification of
transposon gene mutations that co-operate with Etv6-
RUNX1 in leukemia development [7]. Given that PAX5
heterozygosity is a frequent event in ETV6-RUNX1 patients
[5], we bred these mice onto a background of Pax5 hetero-
zygosity and performed a SB transposon-mediated muta-
genesis screen to explore the profile of co-operating drivers.
We coupled this approach with targeted exome sequen-
cing of tumors to find additional mutations, and in par-
ticular hotspot mutation events.
Methods
Mouse strains
Generation and genotyping of Etv6-RUNX1, T2Onc [7] and
Pax5 [8] mice has been described previously. For secondary
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bone marrow transplants of tumors, 6–12 week old SCID
mice were inoculated with 3.5-5 × 105 bone marrow or
spleen cells by tail vein injection. Animal studies were ap-
proved by the Home Office UK. Flow cytometric analysis of
CD antigen expression was performed on single-cell sus-
pensions from spleen or bone marrow as described previ-
ously [7].
Identification and analysis of genes affected by SB
mutagenesis
Isolation of the transposon insertion sites and Gaussian
kernel convolution statistical methods to identify com-
mon insertion sites (CISs) have been described previ-
ously [7]. Whole transcriptome sequencing (RNA-seq)
was performed on splenic RNA using the mRNA Seq
Sample Prep Kit (Illumina, San Diego, CA) to create li-
braries that were sequenced on the Illumina platform.
HTSeq-counts (HTSeq framework; v0.54p5) were used
as input to edgeR (v3.4.2). Genes with significant differ-
ential expression were defined based on an FDR of 5 %.
Pathway and gene set enrichment analysis (GSEA) was
performed using Ingenuity Pathway Analysis and GSEA
(v2.0.14), respectively.
Exome sequencing and bait design
Spleen (‘tumor’) and tail (‘normal’) genomic DNA were
extracted using the Gentra Puregene Cell Kit (Qiagen).
Exon-coding sequences of genes previously found to be in-
volved in cancer were captured using custom-designed
baits (Additional file 1) and sequenced on an Illumina plat-
form. For each tumor-normal pair, MuTect (v1.14) was
used to identify somatic SNVs, which were annotated using
the Variant Effect Predictor tool (Ensembl v74). The Jak1,
Jak3 and Trp53 mutations were validated by capillary
sequencing.
Results and discussion
To perform the SB transposon-mediated mutagenesis
screen we intercrossed Pax5 (Pax5+/−) mice with
transposon-carrying T2Onc mice and the resulting off-
spring were intercrossed with transposase-carrying Etv6-
RUNX1 (Etv6+/RUNX1-SB) mice (Methods). The resulting
genotypes in which transposition would occur were Etv6
+/RUNX1-SB, T2Onc+/Tg, Pax5+/− (hereafter referred to as
ER, Onc, Pax) and Etv6+/RUNX1-SB, T2Onc+/Tg mice (here-
after referred to as ER, Onc). Importantly we found that
ER, Onc, Pax mice showed a significant increase in the
proportion of B-cell precursor (BCP)-ALL cases when
compared to ER, Onc mice wildtype for Pax5 (41/159 (26 %)
versus 1/37 (3 %); p < 0.005 using a 2-tailed Fisher’s
exact test), with 27/41 (66 %) of these cases being B220+
CD19+ (Fig. 1). Additional immunophenotyping of these
B220+ CD19+ cells from ER, Onc, Pax mice confirmed
their ontogenic arrest at the pre-B stage (consistent with
Hardy fraction C’/D and ETV6-RUNX1+ patient leukemic
cells; Fig. 1d). Importantly, the leukemias with an almost
pure population of B220 + CD19+ cells were also trans-
plantable in SCID mice (with recipients developing B-ALL
within 11–55 days; Fig. 1e). RNA-seq analysis performed
on 20 B-ALL cases and 6 age-matched control cases
(ER, Onc, Pax mice that never developed disease) revealed
that 14/34 (41 %) differentially expressed genes were com-
ponents of canonical B cell development pathways
(p = 1.26 × 10−6; Ingenuity Pathway Analysis), while GSEA
revealed a significant enrichment for genes up-regulated in
early B-cell development, specifically the pre-B stage
(Additional file 2: Figure S1). Perturbation of B-cell
homeostasis, in particular a maturation arrest at the pro-/
pre-B stage, is a hallmark of human B-ALL [9]. Thus, our
mouse model and the human disease show significant
similarities, both in terms of differentially expressed
genes and the stage of B-cell arrest. Interestingly we did
not find that Pax5 heterozygosity accelerated leukemia
development (Fig. 1a), suggesting its sole contribution
to B-ALL development in our model is at the level of
the induction of maturation arrest. This is in contrast
to an additional cross we performed in which Etv6
+/RUNX1-SB mice were bred to an Ink4a-deficient back-
ground resulting in a significantly decreased latency to
leukemogenesis (p = 0.0012 using a Log-rank test; Add-
itional file 3: Figure S2), which is in agreement with reports
that INK4A inactivation is associated with an aggressive
clinical course in ETV6-RUNX1+ B-ALL [10].
To define common transposon insertion sites (CISs),
loci in the genome that have increased clustering of
transposon insertion events and hence may contain
candidate driver genes, tumor DNAs from the 20 mice
that developed B220+ CD19+ B-ALL with a tumour cell
fraction >60 % were analysed using 454-based ligand-
mediated PCR sequencing [7]. Six statistically significant
CISs were identified: Jak1, Stat5b, Zfp423, Il2rb, Cblb
and Foxp1 (Fig. 2a). Four of these 6 genes (Zfp423,
Cblb, Stat5b and Foxp1) have well-characterised roles
in regulating B-cell maturation. Analysis of the RNA-
seq data generated from the tumor collection
confirmed that insertions in Zfp423, Jak1 and Stat5b
resulted in significantly increased expression of these
genes (Fig. 2a). Increased ZNF423 expression has been
reported in BCP-ALL (revealing a strong association with
ETV6-RUNX1+ cases) and elevated expression of this gene
has been linked to a B-cell differentiation block [11].
Activation of the JAK/STAT signaling pathway is a
frequent theme in hematological malignancies. In fact,
increased expression of activated STAT5 is correlated
with poor prognosis in ALL patients, and haploinsuffi-
ciency of Pax5 or Ebf1 synergize with constitutively
expressed STAT5 to induce B-ALL [12]. Somatic
mutations of CBL/CBLB in B-ALL typically involve
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Fig. 1 Phenotype of Etv6-RUNX1, T2Onc, Pax5 leukemias. a Kaplan-Meier curves showing the tumor latency of ‘jumping’ Etv6+/RUNX1, T2Onc
+/Tg, Pax5+/− (ER, Onc, Pax) and Etv6+/RUNX1, T2Onc+/Tg (ER, Onc) mice, and ‘non-jumping’ control mice (Onc, Pax and Onc). b The presence of
lymphoblasts in the peripheral blood (PB), spleen, bone marrow and liver from a representative mouse with leukemia. Magnification:
peripheral blood smear (×400), upper row organs (×400) and lower row organs (×1,000). c Classification of the leukemias developed by mice
shown in the Kaplan-Meier curve according to the Bethesda criteria for lymphoid and non-lymphoid murine malignancies. d Upper row:
FACS plots from the bone marrow of a representative mouse demonstrate only background Gr-1/Mac-1 myeloid cells, with the majority of
cells having a B220+/CD19+/surface Ig-. Middle and lower row: FACS plots from the bone marrow of a representative mouse demonstrate
the B220+ cells to have a CD43+, CD127+, AA4.1+, CD24+, BP-1- phenotype. e Survival curves for SCID mice transplanted with 3.5-5 × 105
B220+, CD19+ leukemia cells from ER, Onc, Pax mice and TAPJ23.1a which was an ER, Pax5 mouse. Each color represents a different ‘primary’
leukemia, as indicated by the “TAPJ” name of the mouse (n = 7)
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Fig. 2 Common insertion site and somatic mutation analysis of BCP-ALL cases in Etv6-RUNX1, T2Onc, Pax5 mice. a Transposon common insertion sites
(CIS) in B-ALL cases. All CIS shown have a genome-wide p value of <0.025. Alterations in expression levels were determined using RNA-seq data (from 20
ER, Onc, Pax mice that developed B220+, CD19+ BCP-ALL and 8 age-matched ‘control’ ER, Onc, Pax mice that never developed disease), whereby the
expression level of a gene in BCP-ALL cases containing insertions in a particular CIS was compared to the expression level of that gene in ‘control’ cases.
FC, log fold change; FDR, false discovery rate (significance was assessed at an FDR of 5 %). b Acquired somatic events in B-ALL cases in ER, Onc, Pax mice.
Each column represents a sample (individual mouse). Red indicates a stop mutation, brown indicates a splice acceptor variant, yellow indicates a splice
region variant (intron) and blue indicates a missense variant. c The fraction of reads (expressed as a percentage) reporting the somatic variant alleles shown
in b (in the same order as shown in b). d Schematic diagram of the protein structure of Jak1 and Jak3, showing the locations of the mutations identified
in this study. FERM, band 4.1 ezrin; SH2, src-homology domain. e Somatically acquired mutations in Jak1/3 found in ER, Onc, Pax B-ALL tumors in which
the corresponding JAK1/3 mutations have been found in human cancers. AA, amino acid. *These mutations have been shown to have gain-of-function
and/or transforming activity. **These cases were pediatric high-risk B-cell progenitor ALL excluding BCR-ABL1+ ALL and hypodiploid ALL. ***Acute
megakaryoblastic leukemia of Down syndrome. ****An AML with t(15;17)(q22;q12)
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small deletions affecting the intron/exon boundaries of
exon 8, leading to skipping of this exon and the aboli-
tion of E3 ligase function; the transposon insertions in
Cblb were in intron 8 and thus are likely to function
via a similar mechanism [13]. Mutation of CBL is an
alternative route to activate the RAS pathway [13], and
mutations in RAS have been reported in hyperdiploidy
BCP-ALL and ETV6-RUNX1+ cases [14]. Thus, our
Etv6-RUNX1; Pax5+/− mouse model has several
cardinal genetic features associated with B-ALL.
Interestingly an Etv6+/RUNX1-SB, T2Onc+/+, Pax5+/−
mouse (TAPJ23.1a), in which transposition was not
occuring, developed transplantable B-ALL (Fig. 1e), sug-
gesting a contribution of background somatic mutations
to tumor development leading us to investigate the
somatic mutation landscape by targeted exome sequen-
cing of 404 established cancer genes and candidate B-
ALL drivers in 17 B220 + CD19+ B-ALL cases (Fig. 2b;
Additional file 1). Strikingly the most commonly mu-
tated genes were Jak3 (6/17 mice, 35 %), Trp53 (4/17
mice, 23 %) and Jak1 (2/17 mice, 11 %) with the mis-
sense mutations in Jak1/3 predominantly located in the
pseudokinase domain (Fig. 2d). This domain has been
demonstrated to exert an important negative regulatory
function on the kinase domain [15] with many of the amino
acid changes we identified falling into positions of JAK1/3
reported as being mutated in human leukemias, and shown
to confer gain-of-function or transforming activity (Fig. 2e)
[16–18]. Somatic mutations in JAK1 and JAK3 and have
been reported in adult B-ALL [19] and high-risk/poor
prognosis pediatric B-ALL [20], respectively. The vari-
ant allele frequency of Jak1/3 mutations was around
25 % suggesting that cells with these mutations repre-
sent a major clonal fraction (Fig. 2c). Recurrent som-
atic mutations in Jak1/3 have recently been reported in
B-ALL tumors from Pax5+/- mice [PMID: 25855603],
suggesting that the synergy with Jak mutations in our
model is a result of the knockout allele for Pax5 rather
than the presence of the Etv6-RUNX1 allele. We also
observed somatic Trp53 mutations in our mouse tu-
mors with copy number and/or sequence alterations of
p53 being an independent risk predictor of inferior
outcome/high risk of treatment failure in B-ALL pa-
tients [21, 22].
Conclusions
Collectively, our findings support a model in which
multiple small defects in a network of factors that
regulate B-cell maturation (such as Pax5, Cblb, Zfp423,
Foxp1, and Stat5b) together with activation/inactiva-
tion of oncogenes/tumor suppressor genes (such as the
JAK/STAT signaling pathway and p53) cooperate with
Etv6-RUNX1; Pax5+/− to result in the development B-
ALL. Our transplantable B-ALL tumors represent a
novel tool for assessing potential therapeutic interven-
tion strategies in cases of high risk/poor outcome B-
ALL.
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Additional file 1: List of targeted exome baits. The file contains a list
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genes involved in early B-cell function in our model. (PPT 166 kb)
Additional file 3: Figure S2. Accelerated tumor development in
Ink4a−/−; Etv6+/RUNX1-SB mice. (PPT 162 kb)
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LvdW, GG, BJHP and DJA designed research; LvdW, GG, HO, CDR-E and HK
performed research; LvdW, GG, KW, AGR, BJHP and DJA analysed data; LvdW
and DJA wrote the paper; and all authors critically reviewed and edited the
paper. All authors read and approved the final manuscript.
Acknowledgements
The authors wish to thank the staff of the Research Support Facility at the
Wellcome Trust Sanger Institute for looking after the mice.
L.v.d.W., K.W., A.G.R., C.D.R.-E., and D.J.A. were supported by Cancer Research
UK and the Wellcome Trust (WT098051). C.D.R.-E. was also supported by the
Consejo Nacional de Ciencia y Tecnología of Mexico. B.J.H. and G.G. were
supported by Medical Research Council UK and Cancer Research UK.
Author details
1Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
Cambridge CB10 1HH, UK. 2Cambridge Institute for Medical Research and
Wellcome Trust/MRC Cambridge Stem Cell Institute, Wellcome Trust/MRC
Building, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0XY, UK.
3Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Wellcome
Trust Genome Campus, Hinxton, Cambridge CB10 1HH, UK.
Received: 26 April 2015 Accepted: 27 July 2015
References
1. Mullighan CG. Molecular genetics of B-precursor acute lymphoblastic
leukemia. J Clin Invest. 2012;122:3407–15.
2. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, et al.
TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common
genetic lesion in pediatric ALL and defines a subgroup of patients with an
excellent prognosis. Leukemia. 1995;9:1985–9.
3. Ford AM, Bennett CA, Price CM, Bruin MC, Van Wering ER, Greaves M. Fetal
origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc
Natl Acad Sci U S A. 1998;95:4584–8.
4. Greaves MF, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: lessons in
natural history. Blood. 2003;102:2321–33.
5. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD,
et al. Genome-wide analysis of genetic alterations in acute lymphoblastic
leukaemia. Nature. 2007;446:758–64.
6. Lilljebjörn H, Soneson C, Andersson A, Heldrup J, Behrendtz M, Kawamata N,
et al. The correlation pattern of acquired copy number changes in 164
ETV6/RUNX1-positive childhood acute lymphoblastic leukemias. Hum Mol
Genet. 2010;19:3150–8.
7. Van der Weyden L, Giotopoulos G, Rust AG, Matheson LS, van Delft FW,
Kong J, et al. Modeling the evolution of ETV6-RUNX1-induced B-cell
precursor acute lymphoblastic leukemia in mice. Blood. 2011;118:1041–51.
8. Urbánek P, Wang ZQ, Fetka I, Wagner EF, Busslinger M. Complete block of
early B cell differentiation and altered patterning of the posterior midbrain
in mice lacking Pax5/BSAP. Cell. 1994;79:901–12.
van der Weyden et al. BMC Cancer  (2015) 15:585 Page 5 of 6
9. Zhou Y, You MJ, Young KH, Lin P, Lu G, Medeiros LJ, et al. Advances in the
molecular pathobiology of B-lymphoblastic leukemia. Hum Pathol.
2012;43:1347–62.
10. Papadhimitriou SI, Polychronopoulou S, Tsakiridou AA, Androutsos G,
Paterakis GS, Athanassiadou F. p16 inactivation associated with aggressive
clinical course and fatal outcome in TEL/AML1-positive acute lymphoblastic
leukemia. J Pediatr Hematol Oncol. 2005;27:675–7.
11. Harder L, Eschenburg G, Zech A, Kriebitzsch N, Otto B, Streichert T, et al.
Aberrant ZNF423 impedes B cell differentiation and is linked to adverse
outcome of ETV6-RUNX1 negative B precursor acute lymphoblastic
leukemia. J Exp Med. 2013;210:2289–304.
12. Heltemes-Harris LM, Willette MJL, Ramsey LB, Qiu YH, Neeley ES, Zhang N,
et al. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to
initiate acute lymphoblastic leukemia. J Exp Med. 2011;208:1135–49.
13. Nicholson L, Knight T, Matheson E, Minto L, Case M, Sanichar M, et al.
Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia.
Gene Chromosome Canc. 2012;51:250–6.
14. Case M, Matheson E, Minto L, Hassan R, Harrison CJ, Bown N, et al. Mutation
of genes affecting the RAS pathway is common in childhood acute
lymphoblastic leukemia. Cancer Res. 2008;68:6803–9.
15. Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of Jak2 tyrosine
kinase is dependent on specific regions in its pseudokinase domain. Mol
Biol Cell. 2003;14:1448–59.
16. Sato T, Toki T, Kanezaki R, Xu G, Terui K, Kanegane H, et al. Functional
analysis of JAK3 mutations in transient myeloproliferative disorder and
acute megakaryoblastic leukaemia accompanying Down syndrome.
Br J Haematol. 2008;141:681–8.
17. Choi YL, Kaneda R, Wada T, Fujiwara S-I, Soda M, Watanabe H, et al.
Identification of a constitutively active mutant of JAK3 by retroviral
expression screening. Leuk Res. 2007;31:203–9.
18. Staerk J, Kallin A, Demoulin J-B, Vainchenker W, Constantinescu SN. JAK1
and Tyk2 activation by the homologous polycythemia vera JAK2 V617F
mutation: cross-talk with IGF1 receptor. J Biol Chem. 2005;280:41893–9.
19. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, et al.
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.
J Exp Med. 2008;205:751–8.
20. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA,
Phillips LA, et al. JAK mutations in high-risk childhood acute lymphoblastic
leukemia. Proc Natl Acad Sci U S A. 2009;106:9414–8.
21. Hof J, Krentz S, van Schewick C, Körner G, Shalapour S, Rhein P, et al.
Mutations and deletions of the TP53 gene predict nonresponse to
treatment and poor outcome in first relapse of childhood acute
lymphoblastic leukemia. J Clin Oncol Off J Am Soc Clin Oncol.
2011;29:3185–93.
22. Krentz S, Hof J, Mendioroz A, Vaggopoulou R, Dörge P, Lottaz C, et al.
Prognostic value of genetic alterations in children with first bone marrow
relapse of childhood B-cell precursor acute lymphoblastic leukemia.
Leukemia. 2013;27:295–304.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
van der Weyden et al. BMC Cancer  (2015) 15:585 Page 6 of 6
